Skip to content

UBS downgrades Syngene to ‘sell’ on weak outlook, shares slip 3%

The outlook for Syngene looks weak on a tough marco situation, global headwinds and falling VC funding, said UBS.

Read More

​ The outlook for Syngene looks weak on a tough marco situation, global headwinds and falling VC funding, said UBS. The outlook for Syngene looks weak on a tough marco situation, global headwinds and falling VC funding, said UBS.  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish